✦ LIBER ✦

PP47 First line gefitinib versus first line chemotherapy by carboplatin plus paclitaxel in non-small cell lung cancer patients with EGFR mutations: a phase III study (002) by North East Japan Gefitinib Study Group

✍ Scribed by Y. Minegishi; A. Inoue; K. Kobayashi; A. Gemma; M. Maemondo; S. Oizumi; Y. Saijo; S. Morita; K. Hagiwara; T. Nukiwa

Book ID: 119600930
Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 47 KB
Volume: 7
Category: Article
ISSN: 1359-6349
DOI: 10.1016/s1359-6349(09)72190-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

9LBA A randomized phase III study compar

9LBA A randomized phase III study comparing gefitinib with carboplatin (CBDCA) plus paclitaxel (TXL) for the first-line treatment of non-small cell lung cancer (NSCLC) with sensitive EGFR mutations: NEJ002 study

✍ A. Inoue; K. Kobayashi; M. Maemondo; S. Sugawara; S. Oizumi; Y. Saijo; A. Genma; 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 46 KB

First-line pemetrexed plus cisplatin fol

First-line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian patients with locally advanced or metastatic non-squamous non-small cell lung cancer: A randomised, phase 3 trial

✍ Yang, James Chih-Hsin; Kang, Jin Hyoung; Mok, Tony; Ahn, Myung-Ju; Srimuninnimit 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 507 KB

Phase III, randomized, open-label, first

Phase III, randomized, open-label, first-line study in Asia of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer: evaluation of patients recruited from mainland China

✍ Yi-Long WU; Da-Tong CHU; Baohui HAN; Xuyi LIU; Li ZHANG; Caicum ZHOU; Meilin LIA 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 815 KB

P0066 A randomised phase 3 study compari

P0066 A randomised phase 3 study comparing first-line pemetrexed plus cisplatin followed by gefitinib as maintenance with gefitinib monotherapy in east Asian patients with locally advanced or metastatic non-squamous non-small cell lung cancer

✍ Yang, J.C-H.; Park, K.; Mok, T.; Kang, J.H.; Srimuninnimit, V.; Lin, C.-C.; Kim, 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 37 KB

Biomarker Analyses and Final Overall Sur

Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non-Small-Cell Lung Cancer in Asia (IPASS)

✍ Fukuoka, M.; Wu, Y.-L.; Thongprasert, S.; Sunpaweravong, P.; Leong, S.-S.; Sriur 📂 Article 📅 2011 🏛 American Society of Clinical Oncology 🌐 English ⚖ 241 KB

Paclitaxel and carboplatin as first-line

Paclitaxel and carboplatin as first-line chemotherapy combined with gefitinib (IRESSA) in patients with advanced breast cancer: a phase I/II study conducted by the Hellenic Cooperative Oncology Group

✍ George Fountzilas; Dimitrios Pectasides; Anna Kalogera-Fountzila; Dimosthenis Sk 📂 Article 📅 2005 🏛 Springer US 🌐 English ⚖ 218 KB